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Abstract
Background: Conventional Comparative Genomic Hybridization (CGH) has been widely used for
detecting copy number alterations in cancer and for identifying regions containing candidate tumor
responsible genes. Recently, several studies have shown the utility of cDNA microarray CGH for
studing gene copy changes in various types of tumors. However, no such studies on T-cell
lymphomas have been performed. To date T-cell lymphomas analyzed by the use of chromosome
CGH have revealed only slight copy number alterations and not gene amplifications.
Results: In the present study, we describe the characterization of three amplicons of the T-cell
line huT78 located at 2q34-q37, 8q23-q24 and 20p, where new amplified and overexpressed genes
are found. The use of a cDNA microarray containing 7.657 transcripts allowed the identification of
certain genes, such as BCLX, PCNA, FKBP1A, IGFBP2 and cMYC, that are amplified, highly expressed,
and also contained in the amplicons on 20p and 2q. The expresion of these genes was analyzed in
39 T-cell lymphomas and 3 other T-cell lines.
Conclusion: By the use of conventional CGH and CGH and expression cDNA microarrays we
defined three amplicons in the T-cell line huT78 and identified several novel gene amplifications
(BCLX, PCNA, FKBP1A, IGFBP2 and cMYC). We showed that overexpression of the amplified genes
could be attributable to gene dosage. We speculate that deregulation of those genes could be
important in the development of T-cell lymphomas and/or in the maintenance of T-cell lines.
Background
Gene amplification plays an important role in the pro-
gression and initiation of many solid tumors, as is the case
of breast cancer where amplification of the genes ERBB2
(17q12), cMYC (8q24), and CCND1 (11q13) are found
in 10–25% of breast tumors. Amplifications are revealed
by Comparative Genomic Hybridization (CGH) in small
chromosome areas (restricted to 2–10 Mb) where DNA
copy number increases from more than 5 to 10-fold.
Within these amplicons it is possible to identify critical
amplified genes that are also overexpressed: this is the case
for cMYC (8q24.12), ERBB2 (17q12-q21), MDM2
(12q14.3-q15) or BCL2 (18q21.3) [1-3]. Recently array-
based CGH on cDNA microarrays has been used to
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Using this technique exhaustive analysis of the 17q12 and
17q23 amplicons in breast cancer has led to the identifi-
cation of other genes that are also contained in the ampli-
cons and whose overexpression could also be attributable
to gene amplification [4-8]. Other recent studies in pros-
tate cell lines [9] and in neuroblastoma tumors [10,11]
have also shown the utility of cDNA microarray CGH in
defining amplicon boundaries and in analyzing the com-
plexity of the amplicons. Tumor-related genes contained
in amplicons are identified in these works due to the posi-
bility of correlating gene expression to gene dosage data.
To date, however, no amplifications have been described
in primary tumors or cell lines derived from T-cell lym-
phomas [12,13].
Methods
The cutaneous T-cell line huT78 was obtained from Amer-
ican Type Culture Collection (Rockville, MD) and cells
were grown under recommended culture conditions.
High molecular weight DNA was extracted and CGH was
performed as described previously [12,14].
In order to define regions of high-level amplification and
to identify amplified and highly expressed genes con-
tained in the amplicons, we performed cDNA microarray
experiments on T-cell line huT78 to obtain expression and
genomic profiles of the amplicons. We used the CNIO
Oncochip (v1.1a) containing 7.657 different sequence-
validated I.M.A.G.E cDNA clones (Research Genetics;
Huntsville, AL) -some of them duplicated to reach a total
of 11.718 spots- that represent known genes and
expressed sequence tags (ESTs) related to the tumoral
process, and tissue specific genes. A complete list can be
found at http://bioinfo.cnio.es/data/oncochip/.
Genomic DNA hybridizations on microarrays were per-
formed using DNA extracted from the T-cell line huT78
and from the blood of a control donor used as a reference.
Genomic DNAs were AluI and RsaI digested, labeled with
Cy5 (huT78) and Cy3 (control) using BioPrime labeling
kit (Life Technologies, Inc., Gaithersburg, MD), and
hybridized on microarrays at 50°C for 14–16 h, as previ-
ously described [15]. Post-hybridization washes were per-
formed and microarrays were scanned using a GenePix
scanner (Axon Instruments, Foster City, CA). Fluorescence
ratios Cy5/Cy3 were obtained and normalized by adjust-
ing these ratios to a normalized factor so that the median
of the ratios of all spots in the array equals 1. Only meas-
urements with fluorescence intensities higher than two
times the sum of the background averages' of both fluor-
ochromes (Cy3 and Cy5) were considered reliable. Loga-
rithms of the fluorescence ratios (log2 values) were
calculated and used for the analysis. The CNIO Oncochip
contains 7.657 different clones, of which 3.079 are repli-
cated at least twice: thus, we removed and averaged the
replicates by using an in-house developed preprocessing
tool [16].
Expression data was also obtained from huT78 cells and
from magnetically isolated T lymphocytes obtained from
the pooled peripheral blood of 5 anonymous donors that
were used as a control. T lymphocytes were isolated by
using either magnetic microbeads conjugated to mono-
clonal mouse anti-human CD3 antibodies purchased
from Miltenyi Biotec Inc. (Auburn, CA), or magnetic
depletion of non-T-cells with a cocktail of antibodies
using the Pan T-cell Isolation Kit (Miltenyi Biotec Inc.).
Total RNAs were extracted with Tri Reagent (Molecular
Research Center, Cincinnati, OH) following the manufac-
turer's instructions and amplified using a T7-based
method, as previously described [17,18]. Briefly, 5 µgr of
total RNA were used to produce double-stranded cDNA
(Superscript Choice System, Life technologies Inc.) and
amplification of mRNAs was performed using the Megas-
cript T7 in vitro transcription kit (Ambion, Austin, TX) fol-
lowing manufacturer's recommendations. A pool of
aRNAs obtained from the Universal Human RNA (Strata-
gene, La Jolla, CA) was used as a standard reference in all
hybridizations. Test or reference amplified RNAs (aRNAs)
were labeled with fluorescent Cy5 and Cy3, respectively,
as reported [18] and hybridized on microarrays at 42°C
for 15 hours. Fluorescence ratios (Cy5/Cy3) were normal-
ized and filtered for genomic data. The Cy5/Cy3 ratios
obtained in the cell line hybridization were then com-
pared to those obtained in control T lymphocytes
hybridization.
In order to analyze if the candidate genes contained in the
amplicons are altered in primary tumors and other cell
lines, we analyzed expression data obtained in a previous
study [19] using tumor samples from 39 primary T-cell
lymphomas and 3 cell lines (Jurkat, Molt 16 and Karpas
45). Sample description and clinical details are specified
in the work from Martinez-Delgado et al. [19]. All the
tumors were diagnosed according to the World Health
Organization classification criteria, and all individuals
had given official consent.
Results
CGH studies
CGH carried out in huT78 cells revealed three high-level
gains at 2q34-q37, 8q23-q24 and 20p, showing copy
number gains higher than 5 fold (Figure 1). Low-level
gains and losses of whole chromosomes/chromosomal
regions were also detected in other chromosomes, with
the exception of chromosomes 1, 21 and 22 that did not
show copy number alterations.Page 2 of 10
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Expression and copy number profiling across each chro-
mosome were performed using data from a total of 4.229
tumor-related genes or ESTs that had a map position and
an identity confirmed by in-house sequencing. Map posi-
tions of the cDNA clones were obtained from the
EnsEMBL database http://www.ensembl.org/. According
to this database, clones were ordered along the chromo-
somes and their expression and genomic values (See addi-
tional data file 1 for the raw data used to perform this
analysis) were plotted as a function of their location to
obtain chromosomal genomic and expression profiles
(Figure 2).
Only thirty genes that showed high-level genomic gains
were also highly expressed in the cutaneous T-cell line
huT78 (Table 1). Genes were defined as significantly up-
regulated (or down-regulated) if the difference in ratio to
the control was at least two-fold (log2 [ratio expression
data] ≥ +/-1). Cut-off levels for genomic data were defined
at more than 1.7, a significantly high value to assure that
the gene is gained at least 4-fold (log2 [genomic data] ≥
0,8) (data from FISH studies). Within these thirty genes
that were gained and overexpressed in the cell line, 5 of
them were located in amplicons of chromosome 2
(XRCC5, IGFBP2 and PSMB3) and chromosome 20
(FKBP1A and BCL2L1) revealed by conventional CGH.
Amplicons on chromosomes 20, 2 and 8
Focusing on chromosome 20, the genomic structure of
amplicon at 20p is not continuous, showing a peak of
amplification around 30 Mb on the genes ID1 and
BCL2L1 (BCLX) located at 20q11 (Table 2, Figure 3a).
Both genes are close together (60 Kb apart) and are
CGH and genomic profiles of chromosomes 1, 2, 8 and 20 of the huT78 cell lineFigure 1
CGH and genomic profiles of chromosomes 1, 2, 8 and 20 of the huT78 cell line. Average of the log2 genomic values 
over 3 neighbouring genes are plotted in the figure as a function of the location of the clones according to EnsEMBL database. 
On the right of each graph, CGH profiles show the number of chromosomes analysed (n) and the average profile of the met-
aphases studied with a 99% interval of confidence. Red and green bars at both sides of each ideogram indicate gains or losses. 
Only 4 chromosomes are shown in the figure, chromosome 1 did not present DNA amplification, neither by CGH nor by 
microarray experiments, whilst chromosomes 2, 8 and 20 showed high-level DNA amplification at 2q34-q37, 8q23-q24 and 
20p. On the bottom of each graph amplicons are represented (green bars) and the gain or loss regions (green and red bars, 
respectively). p and q arms are also indicated.
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Molecular Cancer 2005, 4:5 http://www.molecular-cancer.com/content/4/1/5Genomic and expression profiles of chromosomes 2, 8 and 20 of the huT78 cell lineFigure 2
Genomic and expression profiles of chromosomes 2, 8 and 20 of the huT78 cell line. Chromosomes presenting 
regions of high level amplification are shown in the figure. Genomic and expression microarray data (averages of log2 values 
over 3 neighbouring genes) are plotted as a function of the location of the clones. At the foot of each graph amplicons are rep-
resented (gross green bars) along with the gain or loss regions (green and red bars, respectively). p and q arms are also 
indicated.
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labeled and used as a probe for FISH on metaphase
spreads of the cell line showing an extremely high ampli-
fication of this genomic fragment (figure 3b). Surpris-
ingly, not all genes that are highly gained are also
overexpressed when compared to the expression of nor-
mal T-lymphocytes. For example, although ID1 and BCLX
show amplification (4 and 7 times respectively), only
BCLX is highly expressed (Figure 3c). Other genes that are
contained in the amplicon (as defined by conventional
CGH) and that showed an increased copy number (some
of them also overexpressed), such as FKBP1A, CDC25B
and PCNA, were also probed by FISH using BACs RP11-
314N13, RP5-1009E24 and RP4-746J20, respectively
(Figure 3d). These genes are also gained but not in such a
high amplification level as BCLX. These data are observed
in their genomic values (Table 2), thus FISH with the cor-
responding BACs confirmed these results.
Using CGH, amplicon in chromosome 2 is narrower than
amplicon in chromosome 20 (Figure 1). In fact it seems to
be restricted to a few genes if genomic data are examined
(Table 2). Only two areas, one around 220 and the other
around 227 Mb, present the highest genomic values
Table 1: Genes highly gained and overexpressed in huT78 cell line.
Unigene ID Gene Symbol G E Log2(G) Log2(E) Cytogenetic 
Location
Gene
Hs.76884 ID3 1,857 2,343 0,893 1,228 1p36.13-p36.12 inhibitor of DNA binding 3, dominant negative 
helix-loop-helix protein
Hs.84981 XRCC5 2,04 4,044 1,029 2,016 2q35 X-ray repair complementing defective 
repair in Chinese hamster cells 5
Hs.162 IGFBP2 2,563 4,544 1,358 2,184 2q33-34 insulin-like growth factor binding protein 
2
Hs.82793 PSMB3 1,794 3,874 0,843 1,954 2q35 proteasome subunit, beta type, 3
Hs.174007 VHL 3,119 2,044 1,641 1,031 3p26-p25 von Hippel-Lindau syndrome
Hs.55173 CELSR3 1,862 2,647 0,897 1,404 3p24.1-p21.2 cadherin, EGF LAG seven-pass G-type receptor 
3
Hs.180145 HSPC030 1,777 2,947 0,829 1,559 3 HSPC030 protein
Hs.350266 ARGBP2 1,823 2,028 0,866 1,020 4q35.1 Arg/Abl-interacting protein ArgBP2
Hs.179565 MCM3 1,791 4,378 0,841 2,130 6p12 MCM3 minichromosome maintenance deficient 
3
Hs.278589 GTF2I 1,886 2,379 0,915 1,251 7q11.23 general transcription factor II, i
Hs.167246 POR 2,007 2,609 1,005 1,384 7q11.2 P450 (cytochrome) oxidoreductase
Hs.61762 HIG2 1,885 3,152 0,915 1,656 7q32.2 hypoxia-inducible protein 2
Hs.274424 SAS 1,743 4,944 0,802 2,306 9p24.1-p23 N-acetylneuraminic acid phosphate synthase; 
sialic acid synthase
Hs.184793 DKFZP434F195 1,78 2,125 0,832 1,087 9 DKFZP434F195 protein
Hs.18910 POV1 1,78 3,702 0,832 1,888 11p11.2-p11.1 prostate cancer overexpressed gene 1
Hs.91877 THRSP 6,491 3,095 2,698 1,630 11q13.5 thyroid hormone responsive
Hs.180628 DNM1L 1,758 2,715 0,814 1,441 12p12.3 dynamin 1-like
Hs.76294 CD63 1,747 6,165 0,805 2,624 12q12-q13 CD63 antigen (melanoma 1 antigen)
Hs.247888 - 2,284 3,201 1,192 1,679 16
Hs.12303 SUPT6H 1,742 2,819 0,801 1,495 17q11.2 suppressor of Ty 6 homolog (S. cerevisiae)
Hs.296281 ILF1 1,754 3,146 0,811 1,653 17q25 interleukin enhancer binding factor 1
Hs.75716 SERPINB2 2,358 3,767 1,238 1,913 18q21.3 serine (or cysteine) proteinase inhibitor, clade B 
(ovalbumin), member 2
Hs.8372 UQCR 2,046 2,916 1,033 1,544 19p13.3 ubiquinol-cytochrome c reductase subunit
Hs.661 NDUFB7 1,845 2,416 0,884 1,272 19p13.12-
p13.11
NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7
Hs.36992 - 4,848 3,213 2,277 1,684 19
Hs.250615 CYP2A7 1,778 3,718 0,830 1,895 19q13.2 cytochrome P450, subfamily IIA, polypeptide 7
Hs.356727 FKBP1A 1,918 4,022 0,940 2,008 20p13 FK506 binding protein 1A
Hs.305890 BCL2L1 6,941 11,50
8
2,795 3,525 20q11.21 BCL2-like 1, Bcl-X
Hs.273385 GNAS 1,764 2,059 0,819 1,042 20q13.2-q13.3 GNAS complex locus
Hs.284380 GGT1 1,784 2,762 0,835 1,466 22q11.23 gamma-glutamyltransferase 1
Relation of 30 genes presenting genomic values ≥ 1.7 [log2(G) ≥ 0,8] and expression values ≥ 2 [log2(E) ≥ 1]; it represents gains above 4-fold and 
overexpression above 2-fold. In bold, genes located in amplicons. G, Genomic values; E, Expression values.Page 5 of 10
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Genes in amplicon of Chromosome 20
Unigene ID Gene symbol Position (Kb)* Genomic 
values
Expression 
values
Genetic 
data**
Expression 
data**
20p13 Hs.356727 FKBP1A - 1,918 4,022 0,940 2,008
Hs.155140 CSNK2A1 451 n.d. 1,678 n.d 0,747
Hs.156114 PTPNS1 1,505 1,635 0,868 0,709 -0,205
Hs.26045 PTPRA 2,832 1,279 0,251 0,355 -1,997
Hs.89648 AVP 3,051 n.d. 1,274 n.d 0,349
Hs.85004 CENPB 3,753 1,703 1,169 0,768 0,226
Hs.153752 CDC25B 3,765 2,122 1,761 1,079 0,811
Hs.80905 RASSF2 4,748 1,25 0,981 0,322 -0,028
Hs.78996 PCNA 5,083 1,694 8,187 0,760 3,033
Hs.2281 CHGB 5,880 n.d. 0,855 n.d -0,226
Hs.73853 BMP2 6,737 2,694 n.d. 1,430 n.d
Hs.91143 JAG1 10,606 1,89 0,953 0,918 -0,069
Hs.44296 FLJ22324 13,761 1,543 2,292 0,626 1,197
Hs.82306 ADF 17,538 1,43 0,475 0,516 -1,075
Hs.268281 CRN 20,003 1,458 1,034 0,544 0,048
Hs.2030 THBD 23,016 1,655 0,572 0,727 -0,806
Hs.1872 PCK1 24,899 1,482 0,824 0,568 -0,279
Hs.274264 VSX1 25,044 1,67 1,682 0,740 0,750
Hs.75424 ID1 29,981 3,825 1,640 1,935 0,714
20q11 Hs.305890 BCL2L1 30,040 6,941 11,508 2,795 3,525
Genes in amplicon of chromosome 2
Unigene ID Gene symbol Position (Kb)* Genomic 
values
Expression 
values
Genomic 
data**
Expression 
data**
2q34 Hs.54089 BARD1 218,722 0,734 1,646 -0,446 0,719
Hs.84981 XRCC5 220,094 1,823 2,815 0,856 1,341
Hs.162 IGFBP2 220,592 2,563 4,544 1,358 2,184
Hs.107169 IGFBP5 220,635 2,034 0,820 1,024 -0,285
Hs.38125 IFI75 224,000 1,342 1,664 0,413 0,647
Hs.309943 SP140 224,057 1,45 0,646 0,536 -0,631
Hs.83583 ARPC2 226,590 1,058 0,648 0,081 -0,626
Hs.166068 VIL1 226,796 1,025 1,463 0,036 0,549
Hs.82568 CYP27A1 227,154 1,676 0,764 0,745 -0,388
Hs.88049 PRKAG3 227,195 2,091 0,436 1,064 -1,196
Hs.153003 STK16 227,618 1,657 1,272 0,729 0,347
Hs.75318 TUBA1 227,622 1,631 5,622 0,706 2,491
Hs.77768 DNAJB2 227,652 1,82 0,841 0,864 -0,250
Hs.89655 PTPRN 227,662 1,659 1,447 0,730 0,533
Hs.48291 PDE6D 227,901 1,122 0,520 0,166 -0,943
Hs.1734 INHA 228,352 1,187 0,849 0,247 -0,237
Hs.198 PAX3 230,984 1,677 1,504 0,746 0,589
Hs.78946 CUL3 233,252 1,18 0,997 0,239 -0,004
Hs.75498 SCYA20 236,823 1,347 0,293 0,430 -1,769
Hs.91400 HDAC4 243,313 1,26 0,543 0,333 -0,881
Hs.36587 PPP1R7 244,757 0,907 1,859 -0,141 0,895
2q37 Hs.5345 RNPEPL1 245,348 1,488 0,949 0,573 -0,076
2q35 Hs.82793 PSMB3 - 1,794 3,874 0,843 1,954
Genes in amplicon of chromosome 8
Unigene ID Gene symbol Position (Kb)* Genomic 
values
Expression 
values
Genomic 
data**
Expression 
data**
8q23 Hs.114218 FZD6 105,144 0,980 0,621 -0,030 -0,717Page 6 of 10
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XRCC5 (2q35) and IGFBP2 (2q33-24) around 220 Mb,
TUBA1 (tubulin, alpha 1) around 227 Mb and PSMD3
mapped by FISH at 2q35. Amongst these, IGFBP2 is the
most highly overexpressed (Table 2).
Amplicon in chromosome 8 is located at 8q23-q24, where
the gene cMYC is located. This gene was found as
amplified in other tumors and in this study we show that
it is also amplified in the cell line huT78. cMYC is not
however highly expressed in this cell line (Table 2). Chro-
mosome 8 amplicon affects a wide region, from 132 to
146 Mb (shadowed in table 2), but only one gene located
within this area is overexpressed, LY6E (lymphocyte antigen
6 complex, locus E). This gene is upregulated by all-trans-
retinoic acid (ATRA), a differentiation inducer capable of
causing clinical remission in about 90% of patients with
acute promyelocytic leukemia. Other genes located in the
amplicon that have not been analyzed in this study could
also be important.
Analyses of the amplicon candidate genes in primary T-cell 
lymphomas and cell lines
Expression of the relevant genes found in the amplicons
that were gained in this T-cell line were examined in a
series of 39 primary T-cell lymphomas and 3 T-cell lines
(Jurkat, Molt 16 and Karpas 45) [19]. Three genes located
in 20q amplicon were overexpressed in the majority of
primary tumors and stablish cell lines. FKBP1A and PCNA
were overexpressed in 89,7 and 71,8% respectively (35
and 28 out of 39) of the primary tumors and in all the
three cell lines analyzed. In addition, BCLX was overex-
pressed in 64,1% (25/39) of the primary tumors and in
Jurkat cell line. Regarding genes in amplicons of chromo-
some 2 and 8, IGFBP2 was only overexpressed in 15,4%
(6/39) of the tumors and cMYC is not highly expressed in
any of them. However, both genes were overexpressed in
the three cell lines.
Discussion
Conventional chromosome CGH of the T-cell line huT78
showed genomic patterns of copy number changes affect-
ing most of the chromosomes. Three highly amplified
regions were detected using this technique. Nevertheless,
resolution of chromosome CGH is no less than 2 Mb for
copy number gains and is a function of both amplicon
size and copy number gains [20].
In order to precisely define regions of high-level amplifi-
cation and to identify amplified and highly expressed
Hs.86905 ATP6C 105,407 1,067 0,918 0,094 -0,123
Hs.82173 TIEG 105,820 1,277 0,842 0,353 -0,248
Hs.94262 p53R2 106,237 1,324 0,564 0,369 -0,831
Hs.2463 ANGPT1 109,654 1,745 n.d 0,803 n.d.
Hs.106673 EIF3S6 111,104 1.170 0.402 0.227 -1.314
Hs.58189 EIF3S3 119,873 1,097 0,566 0,130 -0,885
Hs.184161 EXT1 121,031 1,260 3,592 0,333 1,845
Hs.174185 ENPP2 122,788 1,223 0,891 0,290 -0,167
Hs.12940 ZHX1 127,568 1,212 1,309 0,277 0,389
Hs.61661 - 127,822 1,101 1,318 0,139 0,399
Hs.181107 ANXA13 127,989 1,333 0,655 0,415 -0,611
Hs.344478 KIAA0196 129,211 1,302 n.d 0,381 n.d
Hs.79070 MYC 132,293 1,883 1,597 0,853 0,630
Hs.305916 TG 136,747 1,441 1,711 0,527 0,775
Hs.75789 NDRG1 137,117 1,617 1,140 0,693 0,190
Hs.157240 MGC4737 143,611 1,722 0,828 0,784 -0,273
Hs.740 PTK3 144,545 1,896 0,939 0,914 -0,487
Hs.77667 LY6E 146,427 1,595 2,410 0,674 1,269
Hs.301118 CYP11B1 146,498 1,619 1,227 0,695 0,295
Hs.348605 - 146,918 1,309 0,826 0,388 -0,276
Hs.264428 TSTA3 147,413 1,365 0,693 0,449 -0,530
Hs.223241 EEF1D 147,485 1,554 3,142 0,636 1,651
Hs.323834 NFKBIL2 147,600 1,375 4,436 0,459 2,149
Hs.339697 LOC51160 147,616 1,418 1,546 0,504 0,629
Hs.31442 RECQL4 147,653 1,458 3,419 0,544 1,774
Hs.12271 - 147,813 1,640 2,034 0,714 1,024
Hs.92679 - 147,876 1,178 1,510 0,236 0,595
8q24 Hs.331601 - 147,927 2,138 1,077 1,096 0,107
Areas of genomic gain presenting the highest values are shown in bold. Note that in 20p amplicon, the entire region is gained, but only the highest 
values are indicated. Underlined are gained and overexpressed genes. *Map location according to the EnsMBL database (with exception of FKBP1A 
and PSMB3 genes that are FISH mapped); **Log2 values; n.d. No data.
Table 2: Genes in amplicons of chromosome 2, 8 and 20. (Continued)Page 7 of 10
(page number not for citation purposes)
Molecular Cancer 2005, 4:5 http://www.molecular-cancer.com/content/4/1/5genes contained in the amplicons of the T-cell line huT78,
we performed cDNA microarray CGH and expression pro-
filing of the cell line. For this purpose, we used the CNIO
Oncochip containing 7.657 different sequence-validated
cDNA clones that represent known genes and expressed
sequence tags (ESTs) related to the tumoral process, and
tissue specific genes.
Recently, several studies have shown the utility of cDNA
microarray CGH for studing gene copy changes in various
types of tumors, and the usefulness of defining amplicon
boundaries at high resolution (gene level) to assist in
locating and identifying candidate oncogenes [4-11].
However, to date, no such studies on T-cell lymphomas
have been performed. In the present study, we determined
the precise locations of gene amplifications in the T-cell
line huT78 by the use of array-based CGH on cDNA
microarrays. We observed that, although chromosome
CGH detected amplicons of different size (as for example
the amplicons on chromosomes 20 and 2), the structure
of those amplicons is more complex when it is analyzed
at high resolution. Amplicon in chromosome 20 extends
a) Microarray genomic values for chromsome 20Figure 3
a) Microarray genomic values for chromsome 20. Note that the entire chromosome 20 has been gained and that, as CGH 
reveals, a peak of amplification is found at 20p. b) FISH with BAC RP11-243J16 (labeled in green) containing ID1 and BCLX 
genes to confirm genomic data; c) Graphical representation of microarray genomic (blue) and expression (pink) values as a 
function of gene position; d) FISH with BAC RP11-314N13 (labeled in red) containing FKBP1A gene on chromosome 20. Met-
aphase spreads from huT78 cells were prepared by standard cytogenetic methods. Gene-specific BAC clones were selected 
from the EnsEMBL database. Clones were labeled with SpectrumGreen-dUTP or SpectrumOrange-dUTP (Vysis) by nick trans-
lation. Dual-color hybridizations were performed at 37°C for 14–16 h and slides were washed and examined using an Olimpus 
AX60 epifluorescence microscope. The specificity and location of each probe was previously confirmed by FISH on normal 
metaphases prior to hybridization on huT78 cells.
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Molecular Cancer 2005, 4:5 http://www.molecular-cancer.com/content/4/1/5along all p arm when detected by use of chromosome
CGH. Instead, several peaks of amplification, different in
magnitude, appear at 3, 5–6, 10 and 29–30 Mbs when
analyzed at gene-by-gene level. Amplicon in chromosome
2, although showing a narrower shape by chromosome
CGH than that of chromosome 20, also presented a
complex structure at high resolution, with two peaks of
amplification around 220 and 227 Mbs.
By analyzing mRNA levels in parallel, we observed that
not all genes that are amplified are also overexpressed.
Thus, by analyzing the expression of the genes contained
in the amplicons, we selected several genes whose expres-
sion seemed to respond to gene copy number gains. We
showed that only a few of the genes contained in the
amplicon are highly gained and also overexpressed. In
this way we could select the candidate genes to study fur-
ther that could be involved in the tumorogenesis of the T-
cell lymphomas.
As stated before [7], however, the elevated expression of
an amplified gene cannot alone be considered strong
independent evidence of a candidate oncogene's role in
tumorigenesis. Thus, we examined the expression of the
selected candidate genes in a series of 39 primary T-cell
lymphomas and 3 T-cell lines (Jurkat, Molt 16 and Karpas
45) [19]. Three genes located in 20q amplicon were over-
expressed in the majority of primary tumors and stablish
cell lines. FKBP1A, PCNA and BCLX were overexpressed in
90–65% of the primary tumors. FKBP1A is a receptor for
rapamicin as well as for FK506, a powerful
immunosuppressant in T-cells, and PCNA is involved in
the control of eukaryotic DNA replication and may have a
role in DNA repair synthesis. BCLX is involved in both
positive and negative regulation of programmed cell
death. Thus, these three genes, could be significant in the
development of T-cell lymphomas.
When the candidate genes located in amplicons of chro-
mosome 2 and 8 were examined, we observed that
IGFBP2 was only overexpressed in a low proportion of the
primary tumors (15%) and cMYC is not highly expressed
in any of them. Curiously, both genes were overexpressed
in the three cell lines suggesting that they could be of rel-
evance in the maintenance of the cell lines.
Conclusions
We have identified 3 amplicons by CGH in the T-cell line
huT78. By cDNA microarray CGH. We have narrowed
down the regions and selected some amplified and over-
expressed genes: BCLX, PCNA and FKBP1A. These genes
are also overexpressed in 65–90% of a set of 39 T-cell lym-
phomas and 3 cell lines, while IGFBP2 and cMYC are only
overexpressed in T-cell lines. Our data suggest a different
role of these genes in such processes. New studies with
more clones covering these amplicons can help us to bet-
ter identify relevant genes in T-cell lymphomas.
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